Kintara Therapeutics Receives Orphan Drug Designation for VAL-083 for Treatment of Diffuse Intrinsic Pontine Glioma (DIPG) Dec 15, 2022
Kintara Therapeutics to Participate at the RHK Capital Disruptive Growth Conference on December 5-6, 2022 Dec 1, 2022
Kintara Therapeutics Granted Fast Track Designation from FDA for REM-001 for Cutaneous Metastatic Breast Cancer Nov 28, 2022
Kintara Therapeutics Presents Three Posters at the 2022 Society for Neuro-Oncology Annual Meeting Nov 18, 2022
Kintara Therapeutics Announces Fiscal 2023 First Quarter Financial Results and Provides Corporate Update Nov 9, 2022
Kintara Therapeutics Pauses REM-001 Program to Conserve Funds to Support VAL-083 International Registrational Study Oct 19, 2022
Kintara Therapeutics Announces Fiscal 2022 Financial Results and Provides Corporate Update Sep 27, 2022
Kintara Therapeutics Announces Three Abstracts Have Been Accepted for the 2022 Society for Neuro-Oncology Annual Meeting Sep 8, 2022
